The efficacy of HSA-DTX@PEG-DVL NPs intargeting TNBC tumors in vivo will be investigated in future studies.Moreover, for further studies, our strategy will be potentially analternative for PD-1/PD-L1-targeted cancer nanotherapy. This evidence concerns the gene CD274 and cancer.